Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
LONDON, May 05, 2017 -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017, at 10:00 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.
A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
Enquiries: GW Pharmaceuticals plc Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
